Lisata Therapeutics Stock Shares Owned By Institutions
| LSTA Stock | USD 3.10 0.08 2.65% |
Lisata Therapeutics fundamentals help investors to digest information that contributes to Lisata Therapeutics' financial success or failures. It also enables traders to predict the movement of Lisata Stock. The fundamental analysis module provides a way to measure Lisata Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Lisata Therapeutics stock.
Lisata | Shares Owned By Institutions |
Lisata Therapeutics Company Shares Owned By Institutions Analysis
Lisata Therapeutics' Shares Owned by Institutions show the percentage of the outstanding shares of stock issued by a company that is currently owned by other institutions such as asset management firms, hedge funds, or investment banks. Many investors like investing in companies with a large percentage of the firm owned by institutions because they believe that larger firms such as banks, pension funds, and mutual funds, will invest when they think that good things are going to happen.
More About Shares Owned By Institutions | All Equity Analysis
Shares Held by Institutions | = | Funds and Banks | + | Firms |
Current Lisata Therapeutics Shares Owned By Institutions | 9.07 % |
Most of Lisata Therapeutics' fundamental indicators, such as Shares Owned By Institutions, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Lisata Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Lisata Shares Owned By Institutions Driver Correlations
Understanding the fundamental principles of building solid financial models for Lisata Therapeutics is extremely important. It helps to project a fair market value of Lisata Stock properly, considering its historical fundamentals such as Shares Owned By Institutions. Since Lisata Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Lisata Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Lisata Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
Since Institution investors conduct a lot of independent research they tend to be more involved and usually more knowledgeable about entities they invest as compared to amateur investors.
| Competition |
Based on the latest financial disclosure, 9.07% of Lisata Therapeutics are shares owned by institutions. This is 79.68% lower than that of the Biotechnology sector and 80.91% lower than that of the Health Care industry. The shares owned by institutions for all United States stocks is 76.87% higher than that of the company.
Lisata Shares Owned By Institutions Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Lisata Therapeutics' direct or indirect competition against its Shares Owned By Institutions to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Lisata Therapeutics could also be used in its relative valuation, which is a method of valuing Lisata Therapeutics by comparing valuation metrics of similar companies.Lisata Therapeutics is currently under evaluation in shares owned by institutions category among its peers.
Lisata Therapeutics Current Valuation Drivers
We derive many important indicators used in calculating different scores of Lisata Therapeutics from analyzing Lisata Therapeutics' financial statements. These drivers represent accounts that assess Lisata Therapeutics' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Lisata Therapeutics' important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 25.9M | 22.1M | 46.5M | 13.1M | 15.1M | 14.3M | |
| Enterprise Value | 24.2M | 12.2M | 6.2M | 22.5M | 25.9M | 36.1M |
Lisata Therapeutics ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Lisata Therapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Lisata Therapeutics' managers, analysts, and investors.Environmental | Governance | Social |
Lisata Fundamentals
| Return On Equity | -0.44 | ||||
| Return On Asset | -0.29 | ||||
| Current Valuation | (10.32 M) | ||||
| Shares Outstanding | 8.39 M | ||||
| Shares Owned By Insiders | 19.12 % | ||||
| Shares Owned By Institutions | 9.07 % | ||||
| Number Of Shares Shorted | 15.09 K | ||||
| Price To Book | 0.75 X | ||||
| EBITDA | (25.52 M) | ||||
| Net Income | (20.84 M) | ||||
| Cash And Equivalents | 72.99 M | ||||
| Cash Per Share | 18.07 X | ||||
| Total Debt | 305 K | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 22.33 X | ||||
| Book Value Per Share | 5.91 X | ||||
| Cash Flow From Operations | (20.03 M) | ||||
| Short Ratio | 1.79 X | ||||
| Earnings Per Share | (2.51) X | ||||
| Price To Earnings To Growth | (0.02) X | ||||
| Target Price | 14.0 | ||||
| Number Of Employees | 25 | ||||
| Beta | 1.22 | ||||
| Market Capitalization | 25.35 M | ||||
| Total Asset | 54.69 M | ||||
| Retained Earnings | (528.08 M) | ||||
| Working Capital | 47.33 M | ||||
| Net Asset | 54.69 M |
About Lisata Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Lisata Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Lisata Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Lisata Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Lisata Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Lisata Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Lisata Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Lisata Therapeutics Stock:Check out Lisata Therapeutics Piotroski F Score and Lisata Therapeutics Altman Z Score analysis. For information on how to trade Lisata Stock refer to our How to Trade Lisata Stock guide.You can also try the Performance Analysis module to check effects of mean-variance optimization against your current asset allocation.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Lisata Therapeutics. If investors know Lisata will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Lisata Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.51) | Return On Assets (0.29) | Return On Equity (0.44) |
The market value of Lisata Therapeutics is measured differently than its book value, which is the value of Lisata that is recorded on the company's balance sheet. Investors also form their own opinion of Lisata Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Lisata Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Lisata Therapeutics' market value can be influenced by many factors that don't directly affect Lisata Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Lisata Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Lisata Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Lisata Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.